

Substitute for form 1449A/PTD

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 3

Complete if Known

Application Number 10/661,780
 Filing Date 09/15/2003
 First Named Inventor PHILIPPE BOUCHARD
 Art Unit 1614
 Examiner Name Brian Yong S. Kwon
 Attorney Docket Number 098501-0305668

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	US-	6,077,523	06/20/2000	Romano Deghenghi	
	US-	6,022,860	02/08/2000	Engel et al.	
	US-				
	US-				
	US-				
	US-				
	US-				
	US-				
	US-				
	US-				
	US-				
	US-				
	US-				
	US-				
	US-				
	US-				
	US-				
	US-				
	US-				

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	†
		Country Code ³ Name ⁴ Kind Code ⁵ (if known)				

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1459, Alexandria, VA 22313-1459. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/BPTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet **2** of **3****Complete if Known**

Application Number	10/661,780
Filing Date	09/15/2003
First Named Inventor	PHILIPPE BOUCHARD
Art Unit	1614
Examiner Name	Brian Yong S. Kwon
Attorney Docket Number	096501-0305998

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	7*
		NESTOR, JR. ET AL., "Potent gonadotropin releasing hormone antagonists with low histamine-releasing activity," J. Med. Chem., Institute of Bio-Organic Chemistry, Vol. 35 (No. 21), p. 3942-3948, (October 16, 1992).	
		DEGHENGHI ET AL., "Antarelix (EP 24332) a novel water soluble LHRH antagonist," Biomed. Pharmacother., Europeptides (Argenteuil, France), Vol. 47 (No. 2-3), p. 107-110, (1993).	
		RIVIER ET AL., "Gonadotropin-releasing hormone antagonists with N omega-triazolylomixine, lysine, or p-aminophenylalanine residues at positions 5 and 6," J. Med. Chem., Salk Institute for Biological Studies (La Jolla, California), Vol. 35 (No. 23), p. 4270-4278, (November 13, 1992).	
	See Attachment 1	HAIV ET AL., "In vitro and in vivo activities of reduced-size antagonists of luteinizing hormone-releasing hormone," J. Med. Chem., TAP Pharmaceuticals, Inc. (Abbott Park, IL), Vol. 37 (No. 5), p. 701-705, (March 4, 1994).	
		WEINBAUER ET AL., "Comparison of the antagonistic activity of three GnRH antagonists (Nal-Glu, Antide and Cetrorelix) in a non-human primate model (Macaca fascicularis)," Andrologia, Institute of Reproductive Medicine of the University (Munster, Germany), Vol. 25 (No. 3), p. 141-147, (May-June 1993).	

Examiner
SignatureDate
Considered

*EXAMINER. Initial if reference considered, whether or not citation is in conformance with MPEP 909. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

† Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.57 and 1.58. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Addendum

Page 3 of 3

Attachment 1

- a.
- b. STOECKEMANN ET AL., "Effects of the luteinizing-hormone-releasing hormone (LHRH) antagonist ramorelix (hoc013) and the LHRH agonist buscrelin or dimethylbenz[*a*]anthracene-induced mammary carcinoma: studies with slow-release formulations," *J. Cancer Res. Clin. Oncol.*, Hoechst AG, Pharma-Research (Frankfurt/Main, Germany), Vol. 119 (No. 8), p. 457-462, (1993).
- c.